

PART I
FORTIS MALAR HOSPITALS LIMITED (CIN: L65110KL1989PL0279486)
 Regd. Office: Escorts Heart Institute and Research Centre, Okhla Road, New Delhi - 110 025
STANDARD ONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2015


Particulars	Standalone		Standalone		Standalone	
	Quarter ended September 30, 2015 (unaudited)	June 30, 2015 (unaudited)	Quarter ended September 30, 2014 (unaudited)	September 30, 2014 (unaudited)	Half year ended September 30, 2015 (unaudited)	Half year ended March 31, 2015 (unaudited)
1						
Income from Operations	3,294.01	3,005.68	2,777.59	6,299.89	5,698.28	11,752.92
a) Income from Operations	1.54	2.72	20.44	4.33	25.36	23.65
b) Other Operating income	3,292.47	3,002.96	3,757.15	6,295.56	5,672.92	11,729.27
Net Income from Operations	3,292.47	3,002.96	3,757.15	6,295.56	5,672.92	11,729.27
2						
Expenses						
a) Drugs and Consumables	68.10	707.65	565.26	1,388.70	1,239.08	2,755.35
b) Employee Benefit Expenses	488.04	408.21	373.46	846.25	780.90	1,567.42
c) Professional Charges to Doctors	856.54	727.89	710.74	1,654.23	1,401.00	2,854.52
d) Clinical Establishment Fees	486.67	454.78	428.93	901.46	851.83	1,753.34
e) Depreciation and amortization Expenses	78.54	78.38	67.90	158.90	126.16	271.18
f) Other Expenses	552.55	570.02	573.67	1,229.77	1,087.73	2,350.36
Total Expenses	3,153.84	2,954.67	2,742.59	6,108.21	5,488.79	11,311.02
3						
Profit from operations before other income, finance costs & exceptional items (1-2)	142.11	53.93	55.44	186.04	166.83	481.55
4						
Other Income	169.18	200.70	162.80	369.89	363.28	736.41
5						
Profit before Finance Costs & Exceptional Items (3 + 4)	311.29	254.63	218.24	555.92	530.12	1,217.96
6						
Finance Cost	9.55	9.19	20.47	19.14	31.43	50.68
7						
Profit after Finance costs but before Exceptional Items and Tax (5 - 6)	321.34	245.44	217.77	536.78	498.69	1,167.28
8						
Exceptional Items						
9						
Profit from Ordinary Activities before Tax (7 - 8)	321.34	245.44	217.77	536.78	498.69	1,167.28
10						
Tax expense	111.50	94.65	77.75	198.15	173.24	491.14
11						
Net Profit from Ordinary Activities After Tax	209.84	160.79	140.01	370.63	325.45	766.94
12						
Extraordinary Items						
13						
Net Profit for the Period / Year	209.84	160.79	140.01	370.63	325.45	766.94
14						
Paid up Equity Share Capital (Face Value Rs.10 each)	1,860.95	1,860.95	1,860.95	1,860.95	1,860.95	1,860.95
15						
Reserves excluding Revaluation Reserves						
16						
Earnings Per Share (EPS) (of Rs. 10 each not annualised for the quarters)						
- Basic	1.13	0.86	0.75	1.99	1.75	4.12
- Diluted	1.13	0.86	0.75	1.99	1.74	4.10
17						
Dividend per Share (Face value of Rs. 10 each)						
- Final Dividend on equity shares (in Rs. per share)						

PART II - Select information for the quarter and half year ended September 30, 2015.

	Quarter ended September 30, 2015 (unaudited)	September 30, 2014 (unaudited)	Quarter ended September 30, 2015 (unaudited)	September 30, 2014 (unaudited)
A				
1				
Public Shareholding	6,841,657	6,841,657	6,841,657	6,841,657
- Number of Shares	36.80%	36.80%	36.80%	36.80%
- Percentage of shareholding				
2				
Promoters and promoters group Shareholding				
a) Pledged / Encumbered				
- No. of shares				
- % of shares (as a % of total shareholding of promoter and promoter group)				
- % of shares (as a % of total share capital of the company)				
b) Non-Encumbered				
- No. of shares	11,752,402	11,752,402	11,752,402	11,752,402
- % of shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
- % of shares (as a % of total share capital of the company)	53.20%	53.20%	53.20%	53.20%

B. INVESTOR COMPLAINTS

Particulars	Quarter ended 30/09/2015
Pending at the beginning of the quarter	0
Received during the quarter	87
Disposed off during the quarter	87
Remains unresolved at the end of the quarter	0




FORTIS MALAR HOSPITALS LIMITED (CIN: L65110D11989PLC276966)
Regd. Office: Escorts Heart Institute and Research Centre, Okhla Road, New Delhi - 110 025
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2015

PARTICULARS	As at September 30, 2015 (Unaudited)	As at March 31, 2015 (Audited)
A. EQUITY AND LIABILITIES		
1. Shareholders' funds		
(a) Share capital	1,080.65	1,080.65
(b) Reserves and surplus	7,555.58	7,184.75
	<u>9,416.33</u>	<u>9,265.70</u>
2. Share application money pending allotment (Refer Note 4)	0.88	
3. Non-current liabilities		
(a) Deferred tax liabilities (net)	44.58	22.65
	<u>44.58</u>	<u>22.65</u>
4. Current liabilities		
(a) Trade payables		
(i) Total outstanding dues of micro enterprises and small enterprises	1,772.47	1,276.94
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	705.03	463.97
(b) Other current liabilities	272.95	184.75
(c) Short-term provisions	2,699.85	1,925.89
	<u>12,161.74</u>	<u>10,914.04</u>
TOTAL - EQUITY AND LIABILITIES		
	<u>21,964.56</u>	<u>19,864.64</u>
B. ASSETS		
1. Non-current assets		
(a) Fixed Assets	2,186.58	1,854.56
(b) Non-current investments	5.00	5.00
(c) Long term loans and advances	152.01	41.42
	<u>2,343.59</u>	<u>1,901.26</u>
2. Current assets		
(a) Inventories	208.23	100.21
(b) Trade receivables	675.99	421.24
(c) Cash and cash equivalents	1,940.33	1,865.85
(d) Short term loans and advances (Refer Note 5)	6,387.21	6,243.60
(e) Other current assets	359.32	460.27
	<u>9,571.25</u>	<u>9,112.66</u>
Sub-total - Current assets		
	<u>12,161.74</u>	<u>10,914.04</u>
TOTAL - ASSETS		
	<u>21,964.56</u>	<u>19,864.64</u>

- The above unaudited financial results have been reviewed by the Audit and Risk Management Committee approved and taken on record by the Board of Directors in their meeting held on October 31, 2015 and have been subjected to a limited review by the Statutory Auditors of the Company.
- The Company has identified business segment which is "Health Care Services" as its primary segment and geographic segment as its secondary segment. The amounts appearing in the results relate to this primary segment.
- During the half year ended September 30, 2015, no equity shares were allotted to its employees by the Company under the Company's Employee Stock Option Scheme (ESOP). The total outstanding employee stock options as at September 30, 2015 is 230,000. During the quarter, the Company has received an amount of Rs. 0.96 lakhs from eligible employees towards exercise of ESOP which is retained as Share Application Money pending allotment as at September 30, 2015.
- Short term loans and advances at September 30, 2015 and March 31, 2015 includes inter-Corporate Deposit with Nalar Stars Medicare Limited, subsidiary of the Company, amounting to Rs. 6,172.34 lakhs which is repayable on demand or before 31 March 2016.
- Previous period figures have been regrouped / reclassified, wherever necessary, to conform with the current period presentation.



By Order of the Board
 For and on behalf of Board of Directors

 Rajeshwar P.
 Whole-time Director


Place: Chennai
 Date: October 31, 2015

INDEPENDENT AUDITORS' REVIEW REPORT TO THE BOARD OF DIRECTORS OF FORTIS MALAR HOSPITALS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **FORTIS MALAR HOSPITALS LIMITED** ("the Company") for the Quarter and Half Year ended 30 September 2015 ("the Statement"), being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreements with the Stock Exchanges, except for the disclosures in Part II - Select Information referred to in paragraph 4 below. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. Further, we also report that we have traced the number of shares as well as the percentage of shareholding in respect of the aggregate amount of public shareholding and the number of shares as well as the percentage of shares pledged/encumbered and non-encumbered in respect of the aggregate amount of promoters and promoter group shareholding in terms of Clause 35 of the Listing Agreement with the Stock Exchange and the particulars relating to investor complaints disclosed in Part II - Select Information for the Quarter and Half Year Ended 30 September 2015 of the Statement, from the details furnished by the Registrar.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)




Sriraman Parthasarathy
Partner
(Membership No. 206834)

Chennai, 31 October, 2015
PS/EKP/2015

PRESS RELEASE

**FORTIS MALAR REPORTS Q2 FY16 REVENUE AT RS.32.96 CR, + 18%
OPERATING PROFIT AT RS 2.11 CR, + 71%
NET PROFIT AT RS 2.10 CR, + 50%**

Chennai, October 31, 2015: Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery provider in India, today announced its results for the quarter ended September 30, 2015.

Commenting on the results Mr Daljit Singh, Chairman, Fortis Malar Hospitals Limited, said, “I am delighted that the hospital achieved its highest ever quarterly revenue numbers which is a result of the investments that your company has made in clinical talent and infrastructure over the past few years, The Company also achieved the unique distinction of completing over 50 heart transplants and 100 cadaver renal transplants which reinforces the position your Company enjoys as a high quality multi-specialty tertiary care centre.

Financial Highlights for the Quarter (Q2FY2016)

- Fortis Malar Hospitals reported operating revenue of Rs 32.96 Cr compared to Rs 27.98 Cr, a growth of 18% over the corresponding quarter of the previous year.
- Operating profit for the quarter stood at Rs 2.11 Cr compared to Rs. 1.23 Cr, a growth of 71% over the corresponding quarter of previous year.
- Net profit was at Rs 2.10 Cr compared to Rs.1.40 Cr, a growth of 50% over the corresponding period of last fiscal.
- During the quarter, Fortis Malar witnessed growth in its key specialties, showing a markedly better performance in Cardiology, Orthopedics, Cosmetic & Plastic Surgery and Health check programmes, which grew by 34%, 23%, 13% and 23% respectively compared to the corresponding quarter of previous year.

Financial Highlights for the Half Year (FY16)

- For the six months period ending September 30, 2015 (H1FY16), Fortis Malar Hospitals reported operating revenue of Rs 63.14 Cr compared to Rs 56.56 Cr, a growth of 12% over the corresponding period of the previous year.
- Operating profit for H1FY16 stood at Rs 3.53 Cr compared to Rs. 2.95 Cr, a growth of 20% over the corresponding period of previous year.

- Net profit was at Rs 3.71 Cr compared to Rs.3.25 Cr a growth of 14% over the corresponding period of last fiscal.

Operational Highlights for the quarter

- Fortis Malar launched “Fortis Senior First Program” in August 2015. The program facilitate Senior Citizens to get priority over the others in treatment with dedicated help lines, reserved seats at OPD , online registration facility & priority in billing counters.
- The expert medical team at the hospital continued to perform high risk and rare surgeries. During the quarter, the team performed the following complex surgeries:
- The Cardiology team at Fortis Malar had successfully completed fifty heart transplants, which is a milestone in the history of Indian healthcare.
- During the quarter, Fortis Malar introduced ECIRS (Endoscopic Combined Intra Renal Surgery) which provides a safe and efficient minimal invasive procedure for the treatment of all kinds of urolithiasis.
- The Hospital also performed 11 renal transplants during the quarter.
- 21 knee replacement and 9 Hip replacement surgeries were also performed at the hospital during the quarter.

Corporate Social Responsibility

Playing its part as a good corporate citizen, Fortis Malar has front ended programme that contribute to society. The hospital actively engaged with the local community meaningfully and organized:

- Health awareness talks, Health checkups and free cardiac camps at various corporate and Government organizations.
- On the occasion of “World Breastfeeding Day” Fortis Malar had organized a health talk on the topics ‘Breastfeeding Management from Obstetrician’ and ‘Use and Misuse of Breastfeeding Accessories’ & emphasizing the importance on breast feeding.
- Provided Free CPR training sessions as part of the Heart saver program at the hospital and at various corporates.
- As part of its Community Connect initiative - “Sunday Conversations” were organized with specialists from Fortis Malar on topical health issues.

About Fortis Malar Hospitals Limited

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopaedics, Gastroenterology, Neurology, Paediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

About Fortis Healthcare Limited

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 54 healthcare facilities (including projects under development), approximately 10,000 potential beds and over 280 diagnostic centres.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

FOR MORE INFORMATION PLEASE CONTACT

Ms. Nandhini.S.
PR & Communications
Fortis Malar Hospitals Ltd
Mobile: 8939831218
Nandhini.s@fortishealthcare.com

Sumit Jain
K2 Communications Pvt Ltd
Mobile: 9886021715
Sumit.jain@k2communications.in